Literature DB >> 29890238

Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial.

Bjorn van Anrooij1, Joanne N G Oude Elberink2, Lambert F R Span3, Jan G R de Monchy2, Stefano Rosati4, André B Mulder5, Johanna C Kluin-Nelemans3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29890238     DOI： 10.1016/j.jaci.2018.06.003

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

Review 1.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

Review 2.  Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Authors:  John H Baird; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 3.  Target Therapies for Systemic Mastocytosis: An Update.

Authors:  Mariarita Sciumè; Claudio De Magistris; Nicole Galli; Eleonora Ferretti; Giulia Milesi; Pasquale De Roberto; Sonia Fabris; Federica Irene Grifoni
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-11

4.  Elevated Basal Serum Tryptase: Disease Distribution and Variability in a Regional Health System.

Authors:  Aubri M Waters; Hyun J Park; Andrew L Weskamp; Allyson Mateja; Megan E Kachur; Jonathan J Lyons; Benjamin J Rosen; Nathan A Boggs
Journal:  J Allergy Clin Immunol Pract       Date:  2022-01-12

Review 5.  Treatment of Indolent and Advanced Systemic Mastocytosis.

Authors:  Alessandro Buonomo; Eleonora Nucera; Marianna Criscuolo
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

6.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

Review 7.  Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.

Authors:  Miguel Piris-Villaespesa; Ivan Alvarez-Twose
Journal:  Front Pharmacol       Date:  2020-04-14       Impact factor: 5.810

8.  Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.

Authors:  Georg Greiner; Michael Gurbisz; Franz Ratzinger; Nadine Witzeneder; Svenja Verena Class; Gregor Eisenwort; Ingrid Simonitsch-Klupp; Harald Esterbauer; Matthias Mayerhofer; Leonhard Müllauer; Wolfgang R Sperr; Peter Valent; Gregor Hoermann
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

Review 9.  Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis.

Authors:  Francesco Mannelli
Journal:  Ann Hematol       Date:  2020-11-06       Impact factor: 3.673
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.